SOLICITATION NOTICE
A -- NIDA Looking for Partners to Advance the Development of Medicines to Treat Tobacco Dependence
- Notice Date
- 3/11/2011
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211 - MSC 9559, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- RFA-DA-11-015_PAR-11-102_RFA-DA-014
- Point of Contact
- Medications Initiative for Tobacco Dependence, Phone: 301-443-9800
- E-Mail Address
-
NIDAMedTDWG@mail.nih.gov
(NIDAMedTDWG@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS NOT A CONTRACT RFP. THIS IS A GRANT FUNDING OPPORTUNITY. The National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health, has launched a major funding initiative to develop more effective smoking cessation medications. NIDA has issued multiple Funding Opportunity Announcements, including Medication Initiative for Tobacco Dependence (MITD): A New Product Development Partnership (PDP) (RFA-DA-11-015). MITD invites cooperative agreement applications from qualified non-profit, private, and academic organizations to form a new Product Development Partnership (PDP), which will then work to develop safe and effective medications for the treatment of tobacco dependence Up to five grants will be awarded for Phase One, the planning phase. Grantees will study the feasibility of novel smoking cessation medications and recommend specific private-public collaborations necessary to successfully support research efforts aimed at development and evaluation of new medications. The ultimate goal of this phase is the establishment of the PDP. Phase Two funding will support a wide array of research and development projects to fulfill the regulatory requirements for approval and marketing in the US. The Phase Two awardee is likely to be chosen from among the Phase One grantees. NIDA intends to commit an estimated $500,000 for Phase One and another $10 million for Phase Two. Other NIDA funding announcements to support the development of new medications for tobacco dependence include the 2011 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (PAR -11-102), 2011 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (RFA-DA-11-009), Predictive Animal Models for Smoking Cessation Medications (RFA-DA-014). Both non-profit and for-profit institutions are eligible to apply. Background: Tobacco smoking is linked to more than 400,000 deaths occurring each year in the United States, and is expected, worldwide, to contribute to over 1 billion premature deaths over the next century. Despite considerable public health efforts, millions remain addicted; the smoking rate has remained unchanged at approximately 20 percent since 2004. Among those trying to quit, the vast majority relapse within 6 months.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/RFA-DA-11-015_PAR-11-102_RFA-DA-014/listing.html)
- Record
- SN02399355-W 20110313/110311234725-e585415fe2673fe144b31a35e817cc6a (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |